Publication:


abstract

BACKGROUND:

A previous study with azelastine nasal spray in patients with seasonal allergic rhinitis (SAR) demonstrated that increasing the azelastine concentration from 0.1% to 0.15% allowed for once-daily dosing without increasing the incidence of adverse effects. This study evaluated the Efficacy of azelastine 0.15% nasal spray administered once daily for treating symptoms of SAR.

METHODS:

In this 14-day, randomized, double-blind, placebo-controlled study, patients with moderate-to-severe SAR were randomized to azelastine 0.15% (n = 251) or placebo (n = 255), both at a dosage of 2 sprays/nostril once daily. The primary efficacy variable was change from baseline in the 12-hour reflective Total Nasal Symptom Score (TNSS). Key secondary variables were change from baseline in 24-hour instantaneous TNSS, to establish the dosing interval, and change from baseline in the Total Ocular Symptom Score (TOSS).

RESULTS:

The mean improvement (3.57) and percentage improvement (19.3%) in 12-hour reflective TNSS was significant (p < 0.012) with azelastine 0.15% compared to placebo (2.14 and 11.4%, respectively). The mean improvement in 24-hour instantaneous TNSS was also significant (p < 0.001) for azelastine 0.15% compared to placebo, indicating efficacy with once-daily dosing. The overall improvement and percentage improvement in TOSS was significant (p ≤ 0.012) with azelastine 0.15% (2.21 and 16.7%, respectively) compared to placebo (1.28 and 6.0%, respectively). The overall score for the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was significantly (p < 0.001) improved from baseline in the azelastine group compared with the placebo group. Nasal discomfort (3.6%) and bitter taste (2.4%) were the most common adverse events. There were no reports of somnolence with azelastine.

CONCLUSION:

Azelastine 0.15% was effective and well tolerated with once-daily dosing. Azelastine 0.15% nasal spray significantly improved a complex of eye symptoms compared to placebo.

Copyright © 2011 American Rhinologic Society-American Academy of Otolaryngic allergy, LLC.

Related Articles
Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis.
Allergy Asthma Proc. 2009
Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis.
van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Allergy Asthma Proc. 2009 Sep-Oct; 30(5):512-8. Epub 2009 Sep 10.
Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis.
Clin Ther. 2005
Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis.
Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H, Azelastine Cetirizine Trial No. 1 (ACT 1) Study Group. Clin Ther. 2005 May; 27(5):543-53.
Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis.
Ann Allergy Asthma Immunol. 2006
Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis.
Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Ann Allergy Asthma Immunol. 2006 Sep; 97(3):375-81.
Review Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.
Curr Med Res Opin. 2007
Review Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.
Bernstein JA. Curr Med Res Opin. 2007 Oct; 23(10):2441-52.
Review Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis.
Drugs. 1998
Review Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis.
McNeely W, Wiseman LR. Drugs. 1998 Jul; 56(1):91-114.